Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MER4101 (MAS-1 Adjuvanted IIV) in Healthy Adults and Elderly
NCT02500680Phase 1Unknown
- Sponsor
- Nova Immunotherapeutics Limited
- Start
- Jul 2015
- Primary completion
- Dec 2020
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MAS-1-adjuvanted seasonal inactivated influenza vaccine in influenza (11 arms), sponsored by Nova Immunotherapeutics Limited. Primary endpoints: Number of Participants with solicited local and systemic AEs at 14 days, Number of Participants with Late-Onset Local and Systemic AEs and 5 more. Status: unknown.
02
Drugs
MAS-1-adjuvanted seasonal inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02500680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500680.